These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 9884677

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Alpha-2 agonists in the treatment of attention deficit hyperactivity disorder.
    Scahill L, Barloon L, Farkas L.
    J Child Adolesc Psychiatr Nurs; 1999; 12(4):168-73. PubMed ID: 10876518
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder.
    Scahill L, Chappell PB, Kim YS, Schultz RT, Katsovich L, Shepherd E, Arnsten AF, Cohen DJ, Leckman JF.
    Am J Psychiatry; 2001 Jul; 158(7):1067-74. PubMed ID: 11431228
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy.
    Pringsheim T, Doja A, Gorman D, McKinlay D, Day L, Billinghurst L, Carroll A, Dion Y, Luscombe S, Steeves T, Sandor P.
    Can J Psychiatry; 2012 Mar; 57(3):133-43. PubMed ID: 22397999
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Extended-Release Guanfacine Does Not Show a Large Effect on Tic Severity in Children with Chronic Tic Disorders.
    Murphy TK, Fernandez TV, Coffey BJ, Rahman O, Gavaletz A, Hanks CE, Tillberg CS, Gomez LI, Sukhodolsky DG, Katsovich L, Scahill L.
    J Child Adolesc Psychopharmacol; 2017 Nov; 27(9):762-770. PubMed ID: 28723227
    [Abstract] [Full Text] [Related]

  • 10. The role of alpha2-adrenergic agonists in attention-deficit/hyperactivity disorder.
    Sallee FR.
    Postgrad Med; 2010 Sep; 122(5):78-87. PubMed ID: 20861591
    [Abstract] [Full Text] [Related]

  • 11. In the pipeline: non-stimulant ADHD meds.
    Glazer WM.
    Behav Healthc; 2010 Jan; 30(1):30-1. PubMed ID: 20184258
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. alpha2-Adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: emerging concepts from new data.
    Arnsten AF, Scahill L, Findling RL.
    J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):393-406. PubMed ID: 17822336
    [Abstract] [Full Text] [Related]

  • 15. Treating ADHD in Prison: Focus on Alpha-2 Agonists (Clonidine and Guanfacine).
    Mattes JA.
    J Am Acad Psychiatry Law; 2016 Jun; 44(2):151-7. PubMed ID: 27236168
    [Abstract] [Full Text] [Related]

  • 16. A review of the rationale and clinical utilization of α2-adrenoceptor agonists for the treatment of attention-deficit/hyperactivity and related disorders.
    Sallee F, Connor DF, Newcorn JH.
    J Child Adolesc Psychopharmacol; 2013 Jun; 23(5):308-19. PubMed ID: 23782125
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The suppression of nightmares with guanfacine.
    Horrigan JP, Barnhill LJ.
    J Clin Psychiatry; 1996 Aug; 57(8):371. PubMed ID: 8752021
    [No Abstract] [Full Text] [Related]

  • 19. Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats.
    Birnbaum SG, Podell DM, Arnsten AF.
    Pharmacol Biochem Behav; 2000 Nov; 67(3):397-403. PubMed ID: 11164065
    [Abstract] [Full Text] [Related]

  • 20. [α2-Adrenergic agonists, and drugs for ADHD].
    Clement HW, Schulz E.
    Pharm Unserer Zeit; 2011 Nov; 40(6):503-9. PubMed ID: 22028136
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.